156 related articles for article (PubMed ID: 36724508)
1. Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure.
Stenger EO; Watkins B; Rogowski K; Chiang KY; Haight A; Leung K; Qayed M; Raghunandan S; Suessmuth Y; Kean L; Horan J
Blood Adv; 2023 May; 7(10):2196-2205. PubMed ID: 36724508
[TBL] [Abstract][Full Text] [Related]
2. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
Watkins B; Qayed M; McCracken C; Bratrude B; Betz K; Suessmuth Y; Yu A; Sinclair S; Furlan S; Bosinger S; Tkachev V; Rhodes J; Tumlin AG; Narayan A; Cribbin K; Gillespie S; Gooley TA; Pasquini MC; Hebert K; Kapoor U; Rogatko A; Tighiouart M; Kim S; Bresee C; Choi SW; Davis J; Duncan C; Giller R; Grimley M; Harris AC; Jacobsohn D; Lalefar N; Norkin M; Farhadfar N; Pulsipher MA; Shenoy S; Petrovic A; Schultz KR; Yanik GA; Waller EK; Levine JE; Ferrara JL; Blazar BR; Langston A; Horan JT; Kean LS
J Clin Oncol; 2021 Jun; 39(17):1865-1877. PubMed ID: 33449816
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease.
Ngwube A; Shah N; Godder K; Jacobsohn D; Hulbert ML; Shenoy S
Blood Adv; 2020 Aug; 4(16):3894-3899. PubMed ID: 32813873
[TBL] [Abstract][Full Text] [Related]
6. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
[TBL] [Abstract][Full Text] [Related]
7. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
8. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
[TBL] [Abstract][Full Text] [Related]
9. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
10. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
11. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.
Auletta JJ; Kou J; Chen M; Bolon YT; Broglie L; Bupp C; Christianson D; Cusatis RN; Devine SM; Eapen M; Hamadani M; Hengen M; Lee SJ; Moskop A; Page KM; Pasquini MC; Perez WS; Phelan R; Riches ML; Rizzo JD; Saber W; Spellman SR; Stefanski HE; Steinert P; Tuschl E; Yusuf R; Zhang MJ; Shaw BE
Transplant Cell Ther; 2023 Jun; 29(6):346.e1-346.e10. PubMed ID: 36924931
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
Soltermann Y; Heim D; Medinger M; Baldomero H; Halter JP; Gerull S; Arranto C; Passweg JR; Kleber M
Ann Hematol; 2019 Jun; 98(6):1485-1493. PubMed ID: 30915500
[TBL] [Abstract][Full Text] [Related]
13. Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients.
Arnold DE; MacMath D; Seif AE; Heimall JR; Wang Y; Monos D; Grupp SA; Bunin NJ
Transplant Cell Ther; 2021 Feb; 27(2):169.e1-169.e9. PubMed ID: 33830028
[TBL] [Abstract][Full Text] [Related]
14. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
Choi SW; Braun T; Henig I; Gatza E; Magenau J; Parkin B; Pawarode A; Riwes M; Yanik G; Dinarello CA; Reddy P
Blood; 2017 Oct; 130(15):1760-1767. PubMed ID: 28784598
[TBL] [Abstract][Full Text] [Related]
15. Abatacept-based Graft-Versus-Host Disease Prophylaxis in Haplo-identical Hematopoietic Cell Transplant in a High-risk Cohort.
Raffa EH; Srinivasan A; Wall DA; Schechter T; Ali M; Krueger J; Chiang KY
J Pediatr Hematol Oncol; 2022 Oct; 44(7):383-387. PubMed ID: 35129143
[TBL] [Abstract][Full Text] [Related]
16. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
[TBL] [Abstract][Full Text] [Related]
17. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning.
Baron F; Storer B; Maris MB; Storek J; Piette F; Metcalf M; White K; Sandmaier BM; Maloney DG; Storb R; Boeckh M
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1176-87. PubMed ID: 17085311
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Follow-Up of Abatacept, Post-Transplantation Cyclophosphamide, and Sirolimus-Based Haploidentical Transplantation in Younger Patients with Nonmalignant Diseases.
Jaiswal SR; Agarwal M; Bhagawati G; Das BC; Baligar P; Garg M; Biswas S; Chakrabarti S
Transplant Cell Ther; 2024 Jun; 30(6):605.e1-605.e13. PubMed ID: 38490295
[TBL] [Abstract][Full Text] [Related]
19. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Bolaños-Meade J; Reshef R; Fraser R; Fei M; Abhyankar S; Al-Kadhimi Z; Alousi AM; Antin JH; Arai S; Bickett K; Chen YB; Damon LE; Efebera YA; Geller NL; Giralt SA; Hari P; Holtan SG; Horowitz MM; Jacobsohn DA; Jones RJ; Liesveld JL; Logan BR; MacMillan ML; Mielcarek M; Noel P; Pidala J; Porter DL; Pusic I; Sobecks R; Solomon SR; Weisdorf DJ; Wu J; Pasquini MC; Koreth J
Lancet Haematol; 2019 Mar; 6(3):e132-e143. PubMed ID: 30824040
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3
Lum SH; James B; Ottaviano G; Ewins AM; Patrick K; Ali S; Carpenter B; Silva J; Tewari S; Furness C; Thomas A; Shenton G; Bonney D; Moppett J; Hambleton S; Gennery AR; Amrolia P; Gibson B; Hough R; Rao K; Slatter M; Wynn R
Transplant Cell Ther; 2024 Mar; 30(3):314.e1-314.e12. PubMed ID: 38103787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
